Your data on MRCVSonline
The nature of the services provided by Vision Media means that we might obtain certain information about you.
Please read our Data Protection and Privacy Policy for details.

In addition, (with your consent) some parts of our website may store a 'cookie' in your browser for the purposes of
functionality or performance monitoring.
Click here to manage your settings.
If you would like to forward this story on to a friend, simply fill in the form below and click send.

Your friend's email:
Your email:
Your name:
 
 
Send Cancel

Update on bTB vaccine

MPs warn vaccine is not a complete solution

In a report published on June 5, the Environment, Food and Rural Affairs Committee (EFRACom), warned that vaccination will not provide a complete solution to bovine TB (bTB).

Launching the report into the progress of a vaccine, EFRACom chair Anne McIntosh said vaccination is expensive, does not guarantee protection and will not on its own solve the problems caused by bTB.

"The Government is right to invest millions of pounds in developing vaccines against bovine TB. We should use every tool to combat this disease, but vaccination alone will not, at least in the short-term, provide a complete solution.

"Vaccines have no impact on already infected animals, offer a range of protection to those that aren’t infected, and will be expensive to deploy."

Small-scale studies in Ethiopia and Mexico have found the protective effect of a cattle vaccine to be 56-68 per cent. EFRACom warn that this is not a high enough level of protection to immediately solve the problem.

The injectable badger vaccine, which has been available since 2010, "could create a healthier badger population", according to Ms McIntosh. It is, however, expensive, she added, meaning it should be used in areas where it will have the most impact.

An oral baited badger vaccine is felt to be "the most likely way to create a healthy badger population," offering a cheaper and more practical alternative to vaccination.

Concluding, Ms McIntosh called on the government to investigate whether the gamma interferon test - a blood test that is more sensitive than the skin test currently relied upon - could be used more widely to test for bTB, despite the cost.

She added that ongoing research projects could make a real difference in eradicating the disease in the UK, and the government's continuing investment in this research is crucial.

 

Related News
Reseach offers hope for bTB vaccine
Cattle bTB vaccine unlikely until 2023

 

Become a member or log in to add this story to your CPD history

Vets launch new podcast for pet owners

News Story 1
 Two independent vets have launched a podcast to help owners strengthen their bond with pets. Dr Maggie Roberts and Dr Vanessa Howie, who have worked in both veterinary practice and major charities, are keen to use their experience to enable people to give pets a better life.

The venture, called Vets Talking Pets, provides advice and information on a range of topics, including how to select a suitable pet, where to obtain them and how to get the best out of your vet. Maggie and Vanessa will also discuss sensitive subjects, including end-of-life care, raw food diets and the cost of veterinary care.

The podcast can be found on all the usual podcast sites, including Podbean, Apple, Amazon Music and YouTube. 

Click here for more...
News Shorts
VMD issues guidance on AVM-GSL packaging

The Veterinary Medicines Directorate (VMD) has shared advice on its requirements for medicines considered AVM-GSL.

The guidance explains the information that should be on the outer package, and sets out the typical maximum pack size for an AVM-GSL product. It also describes the user-friendly language, structure and phrases required on packaging and product leaflets.

AVM-GSL products do not require discussion between the purchaser and a veterinary professional. This means that clear product information is needed to support sales choices.

The information will be useful for submitting new products to the AVM-GSL category and lowering the distribution category of products from NFA-VPS to AVM-GSL.

The VMD's guidance can be accessed here.